Management of disease due to Mycobacterium kansasii

Clinics in Chest Medicine

Volumn 23, Issue 3, 2002, Pages 613-621

  Griffith, David E ^a  

^a Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPRENAVIR; ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; CIPROFLOXACIN; CLARITHROMYCIN; DELAVIRDINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; INDINAVIR; ISONIAZID; MOXIFLOXACIN; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STREPTOMYCIN; SULFAMETHOXAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CIGARETTE SMOKING; CLINICAL FEATURE; CLINICAL PROTOCOL; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM; MYCOBACTERIUM KANSASII; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; THORAX RADIOGRAPHY;

ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM KANSASII; RADIOGRAPHY, THORACIC; SPUTUM; TUBERCULOSIS, PULMONARY;

EID: 0036739620     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(02)00016-3     Document Type: Review

References (32)

1. Lillo M, Orengo S, Cemoch P, et al. Pulmonary and disseminated infection due to Mycobacterium kansasii: a decade of experience. Rev Infect Dis 1990; 12:760-7.
2. Steadman JE. High-catalase strains of Mycobacterium kansasii isolated from water in Texas. J Clin Microbiol 1980;11:496-8.
3. Engel HWB, Berwald LG, Havelaar AH. The occurrence of Mycobacterium kan-sasii in tap water. Tubercle 1980;61:21-6.
4. Engel HWB, Berwald LG, Lindeboom BW, Havelaar AH. Mycobactetium kansasii infections in the Netherlands: a brief summary. Rev Infect Dis 1981;3:1024.
5. Picardeau M, Prod'holm G, Raskine L, LePennec MP, Vincent V. Genotypic characterization of five subspecies of Mycobacterium kansasii. J Clin Microbiol 1997; 35:25-32.
6. Zhang Y, Mann LB, Wilson RW, et al. Molecular analysis of Mycaobacterium kansasii isolates from the United States. Presented at the ASM 101st General Meeting, Orlando, Florida; May 2001. Abstract #U-14.
7. Jenkins PA. The epidemiology of opportunist mycobacterial infections in Wales, 1952-1978. Rev Infect Dis 1981;3:1021-3.
8. Yates MD, Grange JM, Collins CH. The nature of mycobacteria disease in south east England, 1977-84. J Epidemiol 1986;40:295-300.
9. Bittner MJ, Horowitz EA, Safranek TJ, Preheim LC. Emergence of Mycobactelium kansasii as the leading mycobacterial pathogen isolated over a 20-year period at a midwestern Veterans Affairs hospital. Clin Infect Dis 1996;22:1109-10.
10. Ahn CH, Lowell JR, Onstad GD, Shuford EH, Hurst GA. A demographic study of disease due to Mycobactetium kansasii or M intracellulare-avium in Texas. Chest 1979;75:120-5.
11. Bloch KC, Zwerling L, Pletcher MJ, Hahn JA, Gerberding JL, Ostroff SM, et al. Incidence and clinical implications of isolation of Mycobacterium kansassi: results of a 5-year, population-based study. Ann Intern Med 1998;129:698-704.
12. Corbett EL, Churchyard GJ, Hay M, Herselman P, Clayton T, Williams B, et al. The Impact of HIV infection on Mycobacterium kansassi disease in South African miners. Am J Respir Crit Care Med 1999; 160:10-4.
13. Corbett EL, Blumberg L, Churchyard GJ, Moloi N, Mallory K, Clayton T, et al. Nontuberculous mycobacteria defining disease in a prospective cohort of South African miners. Am J Respir Crit Care Med 1999; 160:15-21.
14. Jocobson KL, Teira R, Libshitz HI, Raad I, Rolston KVI, Tarrand J, et al. Mycobacterium kasassi infections in patients with cancer. Clin Inf Dis 2000;30:965-9.
15. Griffith DE, Brown-Elliott BA, Wallace RJ Jr. An intermittent clarithromycin (CLARI)-containing regiman for Mycobacterium kansasii. Am J Respir Crit Care Med 2001;163:762.
16. Levine B, Chaisson RE. Mycobactetium kansasii: a cause of treatable pulmonary disease associated with advanced human immunodeficiency virus (HIV) infection. Ann Intern Med 1991;114:861-8.
17. Witzig RS, Fazal BA, Mera RM, et al. Clinical manifestations and implications of coinfection with Mycobacterium kansasii and human immunodeficiency virus type 1. Clin Infect Dis 1995;21:77-85.
18. Parenti DM, Symington JS, Keiser J, Simon GL. Mycobacterium kansasii bacteremia in patients infected with human immunodeficiency virus. Clin Infec Dis 1995;21:1001-3.
19. Wallace Jr RJ, Glassroth J, Griffith DE, et al. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997;156: 51-525.
20. Ahn CH, Wallace Jr RJ, Steele LC, Murphy DT. Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii. Am Rev Respir Dis 1987;135:10-6.
21. Gay JD, DeYoung DR, Roberts GD. In vitro activities of norfloxacin and ciprofloxacin against Mycobactefium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii. Antimicrob Agents Chemother 1984;26:94-6.
22. Pezzia W, Raleigh JW, Bailey MC, Toth EA, Silverblatt J. Treatment of pulmonary disease due to Mycobactetium kansasii: recent experience with rifampin. Rev Infect Dis 1981;3:1035-9.
23. Wallace Jr RJ, Dunbar D, Brown BA, et al. Rifampin-resistant Mycobacterium kansasii. Clin Infect Dis 1994;18:736-43.
24. Ahn CH, Lowell JR, Ahn SA, Ahn S, Hurst GA. Chemotherapy for pulmonary disease due to Mycobacterium kansasii: efficacies of some individual drugs. Rev Infect Dis 1981;3:1028-34.
25. Ahn CH, Lowell JR, Ahn SA, Ahn SI, Hurst GA. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am Rev Respir Dis 1983;128:1048-50.
26. Banks J, Hunter AM, Campbell IA, Jenkins PA, Smith AP. Pulmonary infection with Mycobacterium kansasii in Wales, 1970-9: review of treatment and response. Thorax 1983;38:271-4.
27. Jenkins DE, Bahar D, Chofuas I. Pulmonary disease due to atypical mycobacterial: current concepts. Trans 19th Conf on Chemotherapy of Tuberculosis 1960; 224-31.
28. Jenkins PA, Banks J, Campbell IA, Smith PA. Research Committee, British Thoracic Society. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambatol. Thorax 1994;49:442-5.
29. Sauret J, Hemandez-Flix S, Castro E, Hernandez L, Ausina V, Coll P. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy. Tubercle and Lung Dis 1995;76:104-8.
30. Burman WJ, Jones BE. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med 2001;164:7-12.
31. McSwiggan DA, Collins CH. The isolation of M. kansasii and M. xenopi from water systems. Tubercle 1974;55:291-7.
32. Department of health and human services. Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents. Available at: http://www.hivatis.org. Accessed February 4, 2002.